Leap Therapeutics, Inc. (NASDAQ:LPTX) tinted loss of 0% (0 points) to US$1.56. The volume of 0.73 Million shares climbed down over an trading activity of 255.77 Million shares. EPS ratio determined by looking at last 12 month figures is -3.45. Over the same time span, the stock marked US$10.25 as its best level and the lowest price reached was US$1.35. The corporation has a market cap of US$33.82 Million.
Leap Therapeutics, Inc. (NASDAQ:LPTX)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -271.4 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 41.5 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 1 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.67. 2 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Novelion Therapeutics Inc. (NASDAQ:NVLN) is worth US$24.35 Million and has recently risen 7.81% to US$1.38. The latest exchange of 0.47 Million shares is below its average trading activity of 919.54 Million shares. The day began at US$1.29 but the price moved to US$1.28 at one point during the trading and finally capitulating to a session high of US$1.38. The stock tapped a 52-week high of US$5.32 while the mean 12-month price target for the shares is US$6.5.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 0, and a price to sales ratio of 0.19. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown -10%. With an institutional ownership near 76.5%, it carries an earnings per share ratio of -6.05.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 0 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 3.